JPH11130669A - Amino acid-based nutrient preparation for preventing/ treating bedsore - Google Patents

Amino acid-based nutrient preparation for preventing/ treating bedsore

Info

Publication number
JPH11130669A
JPH11130669A JP9295222A JP29522297A JPH11130669A JP H11130669 A JPH11130669 A JP H11130669A JP 9295222 A JP9295222 A JP 9295222A JP 29522297 A JP29522297 A JP 29522297A JP H11130669 A JPH11130669 A JP H11130669A
Authority
JP
Japan
Prior art keywords
amino acid
mol
treatment
present
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9295222A
Other languages
Japanese (ja)
Inventor
Norimoto Ishizuka
紀元 石塚
Shinichi Suzuki
伸一 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP9295222A priority Critical patent/JPH11130669A/en
Publication of JPH11130669A publication Critical patent/JPH11130669A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To develop and obtain a nutrient composition useful for the systemic therapy or prevention of bedsore. SOLUTION: This amino acid-based nutrient preparation and a related nutrient food each contains the following amino acids in the corresponding proportions: L-arginine 6.0-21.0 mol.%, L-isoleucine 6.0-20.0 mol.%, L-leucine 8.0-25.0 mol.%, L-valine 6.0-19.0 mol.%, L-lysine 1.0-6.0 mol.%, methionine 2.0-8.0 mol.%, L-threonine 4.0-13.0 mol.%, L-histidine 1.0-6.0 mol.%, L-proline 3.0-9.0 mol.%, L-phenylalanine 0.2-1.0 mol.%, L-tryptophan 0.1-1.0 mol.%, and L- glutamine 8.0-27.0 mol.%.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、褥瘡患者の治療過
程で必要な、組織の再生を促進する褥瘡治療剤および褥
瘡予防治療用食品に関し、更に詳しくは、有効成分とし
て、特定のアミノ酸を特定の割合で含有することを特徴
とする褥瘡予防治療用アミノ酸栄養剤および褥瘡予防治
療用アミノ酸栄養食品に関するものである。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a therapeutic agent for pressure ulcer and a food for prevention and treatment of pressure ulcer, which are required in the treatment process of a patient with pressure ulcer, and more specifically to a specific amino acid as an active ingredient. The present invention relates to an amino acid nutrient for pressure ulcer prevention and treatment and an amino acid nutritional food for pressure ulcer prevention and treatment characterized by containing at a ratio of:

【0002】[0002]

【従来の技術】近年の医療技術の発達は多くの人命を救
うことを可能にしたが、その一方で多くのAbilit
y of Daily Life(ADL 日常生活能
力)の低下した要介護者が生み出されていることも否定
できない事実である。そのような要介護者における褥瘡
(床擦れ)の存在は本人のみならず介護者にも精神的、
身体的に極めて大きな負担になり療養の継続に大きな影
響を及ぼすものである。
2. Description of the Related Art Recent advances in medical technology have made it possible to save many lives, while many Abilites have been saved.
It is an undeniable fact that care-requirers with reduced y of Daily Life (ADL daily living ability) have been created. The presence of pressure ulcers (rubbing on the floor) in such care recipients is mentally
This is an extremely heavy physical burden and has a great effect on the continuation of medical treatment.

【0003】褥瘡は、皮膚が圧迫されることにより局所
の血流が阻害され、その結果皮膚組織が循環不全により
傷害される状態である。軽症のものでは皮膚表面のびら
んに止どまるが、重症のものでは皮下組織から骨、靱帯
に至る皮膚潰瘍を形成し極めて難治、場合によっては細
菌感染から死に至ることもある。例えば、高齢者の敗血
症や肺炎による死亡率が高いが、その原発感染病巣とな
るのが褥瘡である。また、褥瘡は感染、保菌を問わず、
その分泌物中に多量の細菌を保有し、病院内感染対策上
も問題となりうるものである。
[0003] Pressure ulcers are conditions in which local blood flow is impaired due to pressure on the skin, and as a result, skin tissue is injured by circulatory failure. In mild cases, it stops at the erosion on the skin surface. In severe cases, skin ulcers form from the subcutaneous tissue to the bones and ligaments, and are extremely intractable. In some cases, bacterial infection can lead to death. For example, elderly people have a high mortality rate due to sepsis or pneumonia, but the primary infection focus is pressure sores. Pressure ulcers can be infected or colonized,
It has a large amount of bacteria in its secretions, which can be a problem in infection control in hospitals.

【0004】従来、褥瘡の治療は、1)体位の変換と除
圧、2)創傷部の消毒、3)壊死組織の除去、4)創傷
治癒促進、5)創傷保護等に大別される。このうち4)
の創傷治癒促進を除く治療法はいずれも褥瘡の進展を抑
える点では有効な治療法ではあるが、褥瘡の治癒過程に
直接関与し治癒を促進する方法ではない。また、4)の
創傷治癒促進については、近年、比較的有用な治療薬の
開発が為されているが、褥瘡に罹患している患者が極め
て低栄養状態であることから、十分な治療成績を得るに
至っていない。
[0004] Conventionally, treatment of pressure ulcers is roughly classified into 1) change of body position and decompression, 2) disinfection of wound sites, 3) removal of necrotic tissue, 4) promotion of wound healing, 5) protection of wounds, and the like. 4)
Although all treatments except for the promotion of wound healing are effective treatments in suppressing the development of pressure ulcers, they are not directly involved in the healing process of pressure ulcers and are not methods of promoting healing. Regarding the promotion of wound healing in 4), relatively useful therapeutic agents have been developed in recent years. However, since patients suffering from pressure ulcers are extremely malnourished, sufficient therapeutic results can be obtained. I haven't gotten it.

【0005】褥瘡の治癒は創傷部における肉芽の新生・
皮膚潰瘍の閉鎖等、組織の再構築を必要とするが、これ
には全身的療法としての経口栄養摂取の徹底が良性肉芽
組織の増生の見地から最も良い方法である。特にこれら
の組織の再構築にはアミノ酸や蛋白質を十分に摂取する
ことが必須である。それにもかかわらず、一般には褥瘡
患者は経口摂取困難であることが多いため、低栄養状態
であることが多く、各種の褥瘡の治療法は十分な成績を
得るには至っていない。
[0005] The healing of pressure ulcers depends on the formation of granulation at the wound site.
Tissue remodeling, such as closure of skin ulcers, is required, but thorough oral nutrition as a systemic therapy is the best method from the standpoint of benign granulation tissue growth. In particular, in order to reconstruct these tissues, it is essential to take in amino acids and proteins sufficiently. Nevertheless, in general, pressure ulcer patients often have difficulty in oral ingestion, so they are often undernourished, and treatment methods for various pressure ulcers have not achieved satisfactory results.

【0006】[0006]

【発明が解決しようとする課題】前項記載の従来技術の
背景下に、本発明は、従来の栄養摂取を改善することに
より各種の褥瘡の治療法に十分な成績を収めさせるこ
と、および褥瘡を予防することを目的とする。
In the context of the prior art described in the preceding paragraph, the present invention provides a method for treating various pressure ulcers by improving the conventional nutritional intake, and improving the pressure ulcer treatment. The purpose is to prevent.

【0007】[0007]

【課題を解決するための手段】本発明者は、前項記載の
目的を達成すべく鋭意研究の結果、特定のアミノ酸を特
定の割合で褥瘡患者に摂取せしめることが褥瘡治癒に有
効なること、および前記特定のアミノ酸を前記特定の割
合で褥瘡の生ずる恐れのある病臥者に摂取せしめること
が褥瘡の予防に有効なることを見いだし、このような知
見に基いて本発明を完成するに至った。
Means for Solving the Problems As a result of intensive studies to achieve the object described in the preceding section, the present inventor has found that ingesting a specific amino acid to a pressure ulcer patient at a specific ratio is effective for pressure ulcer healing, and It has been found that ingesting the specific amino acid at the specific ratio to a patient suffering from pressure ulcer may be effective in preventing pressure ulcer, and the present invention has been completed based on such findings.

【0008】すなわち、本発明は、有効成分として、下
記アミノ酸を下記割合(モル比(%))で含有すること
を特徴とする褥瘡予防治療用アミノ酸栄養剤に関する。
That is, the present invention relates to an amino acid nutrient for the prevention and treatment of pressure ulcers, which comprises the following amino acids as active ingredients in the following ratio (molar ratio (%)).

【0009】L−アルギニン6.0〜21.0、L−イ
ソロイシン6.0〜20.0、L−ロイシン8.0〜2
5.0、L−バリン6.0〜19.0、L−リジン1.
0〜6.0、メチオニン2.0〜8.0、L−スレオニ
ン4.0〜13.0、L−ヒスチジン1.0〜6.0、
L−プロリン3.0〜9.0、L−フェニルアラニン
0.2〜1.0、L−トリプトファン0.1〜1.0お
よびL−グルタミン8.0〜27.0。
L-arginine 6.0-21.0, L-isoleucine 6.0-20.0, L-leucine 8.0-2
5.0, L-valine 6.0-19.0, L-lysine
0-6.0, methionine 2.0-8.0, L-threonine 4.0-13.0, L-histidine 1.0-6.0,
L-proline 3.0-9.0, L-phenylalanine 0.2-1.0, L-tryptophan 0.1-1.0 and L-glutamine 8.0-27.0.

【0010】本発明は、また、有効成分として、上記ア
ミノ酸を上記の割合で含有することを特徴とする褥瘡予
防治療用アミノ酸栄養食品に関する。
[0010] The present invention also relates to an amino acid nutritional food for preventing and treating pressure ulcers, which comprises the above-mentioned amino acid as an active ingredient in the above-mentioned ratio.

【0011】本発明は、高齢者において最も効果的に蛋
白合成を促進する、いくつかの必須アミノ酸に着目し、
これらのアミノ酸を少量投与することにより、従来の栄
養療法や薬剤による治療法で十分な治療効果が図れなか
った褥瘡患者の治療や褥瘡の予防を可能にしたのであ
る。
[0011] The present invention focuses on several essential amino acids that most effectively promote protein synthesis in the elderly,
By administering small amounts of these amino acids, it was possible to treat pressure ulcer patients and prevent pressure ulcers, for which conventional nutritional treatments and treatments with drugs could not achieve a sufficient therapeutic effect.

【0012】[0012]

【発明の実施の形態】以下、本発明を詳細に説明する。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below in detail.

【0013】本発明にいう特定のアミノ酸とは、L−ア
ルギニン、L−イソロイシン、L−ロイシン、L−バリ
ン、L−リジン、メチオニン、L−スレオニン、L−ヒ
スチジン、L−プロリン、L−フェニルアラニン、L−
トリプトファンおよびL−グルタミンである。メチオニ
ンはL−体およびDL−体の何れをも使用できるが、L
−体の方が好ましい。
The specific amino acids referred to in the present invention include L-arginine, L-isoleucine, L-leucine, L-valine, L-lysine, methionine, L-threonine, L-histidine, L-proline and L-phenylalanine. , L-
Tryptophan and L-glutamine. Methionine can be used in either the L-form or the DL-form.
-The body is preferred.

【0014】本発明で使用する各アミノ酸は、投与経路
にもよるが、各々、単品で高純度のものが好ましい。例
えば、「食品添加物公定書」に規定する純度以上のアミ
ノ酸を使用する。また、これらのアミノ酸としては、そ
の生理学的に許容し得る塩の形態のものも使用可能であ
る。例えば、L−リジン塩酸塩、L−ヒスチジン塩酸塩
1水和物などである。
Although each amino acid used in the present invention depends on the administration route, it is preferable that each amino acid is a single product and has high purity. For example, an amino acid having a purity equal to or higher than that specified in the “Food Additive Standard” is used. These amino acids may be in the form of their physiologically acceptable salts. For example, L-lysine hydrochloride, L-histidine hydrochloride monohydrate, etc.

【0015】なお、食用蛋白を酸または酵素により加水
分解して取得するアミノ酸混合物を原料として使用する
こともできる。その際には、個別のアミノ酸について過
不足分を調整して、規定するアミノ酸の構成比率に適合
せしめて使用すれば良い。
An amino acid mixture obtained by hydrolyzing an edible protein with an acid or an enzyme may be used as a raw material. In this case, the excess or deficiency of each amino acid may be adjusted so as to be adapted to the specified amino acid composition ratio before use.

【0016】本発明の褥瘡予防治療用アミノ酸栄養剤
は、例えば前記のアミノ酸を前記の割合で粉末状態で均
一に混合することで製造することができる。その具体的
な方法に関しては、特に限定はない。例えば、粉砕した
各アミノ酸をロッキングミキサーを使用して混合する方
法などが採用できる。また、溶液状態で混合し、その後
に乾燥することもできる。これらの操作は室温(25
℃)以下で行うのが望ましい。
The amino acid nutrient for the prevention and treatment of pressure ulcer of the present invention can be produced, for example, by uniformly mixing the above-mentioned amino acids in the above-mentioned ratio in a powder state. There is no particular limitation on the specific method. For example, a method of mixing the pulverized amino acids using a rocking mixer can be employed. Alternatively, they can be mixed in a solution state and then dried. These operations are performed at room temperature (25
℃) or lower.

【0017】アミノ酸栄養剤を製造する際に、必要なア
ミノ酸以外の成分を、必要に応じて若しくは所望によ
り、添加することもできる。これらの添加成分として
は、(イ)低熱量性の糖質、例えば還元麦芽糖、還元乳
糖、トレハロース、オリゴ糖類、(ロ)苦味性を有する
アミノ酸の苦味性をマスクする作用のある物質、例えば
包接能を有する物質であるシクロデキストリン、(ハ)
食品香料、(ニ)食用色素、例えばベータ・カロチン、
(ホ)各種のビタミン類を含有するビタミン・ミック
ス、(ヘ)各種のミネラル類を含有するミネラル・ミッ
クス、(ト)低熱量性の甘味料、例えば「アスパルテー
ム」、(チ)酸味料、例えばクエン酸無水物、(リ)成
型助剤、例えば長鎖脂肪酸エステル、および(ヌ)本発
明のアミノ酸栄養剤を構成するアミノ酸以外のアミノ
酸、例えばグリシン、L−アラニンなどが挙げられる。
In producing an amino acid nutrient, components other than necessary amino acids can be added as necessary or desired. Examples of these additional components include (a) low-caloric saccharides, such as reduced maltose, reduced lactose, trehalose, oligosaccharides, and (b) substances having an action of masking the bitterness of amino acids having bitterness, for example, packaging. (C) cyclodextrin, a substance capable of functioning
Food flavors, (d) food dyes, such as beta-carotene,
(E) a vitamin mix containing various vitamins, (f) a mineral mix containing various minerals, (g) a low calorific sweetener, for example, "aspartame", (h) an acidulant, Examples include citric anhydride, (i) a molding aid such as a long-chain fatty acid ester, and (nu) an amino acid other than the amino acids constituting the amino acid nutrient of the present invention, such as glycine and L-alanine.

【0018】なお、アミノ酸栄養剤に添加する成分とし
て、通常の熱量を有する糖類あるいは甘味料、すなわ
ち、ショ糖、グルコース、フルクトース、蜂蜜などは、
接食者に過剰の熱量を供給する結果となることがある。
このような場合には、必要以上の添加は回避すべきであ
ることはもちろんである。
As components added to the amino acid nutrient, saccharides or sweeteners having a normal calorific value, that is, sucrose, glucose, fructose, honey, etc.
This can result in providing excess heat to the eater.
In such a case, it is needless to say that excessive addition should be avoided.

【0019】このようにして製造された本発明の褥瘡予
防治療用アミノ酸栄養剤は、そのまま、すなわち、粉体
混合物の形態で流通に置くことができる。
The thus prepared amino acid nutrient for the prevention and treatment of pressure ulcer of the present invention can be distributed as it is, that is, in the form of a powder mixture.

【0020】また、その投与は、経口投与、経腸投与、
輸液による経静投与など一般的投与経路を経ることがで
きるが、投与経路により適当な剤形に調製して流通に置
くことができる。
The administration may be oral, enteral,
The drug can be administered through a common administration route such as intravenous administration by infusion, but it can be prepared into an appropriate dosage form depending on the administration route and placed in distribution.

【0021】例えば、経口投与の場合には、服用者に違
和感を与えることなく容易に受容され得る形態であれば
特別の制限はなく、上記組成を有するアミノ酸組成物自
体として、あるいは医薬上許容される担体、賦活剤、希
釈剤などとともに混合し、散剤、顆粒剤、錠剤、カプセ
ル剤、トローチ剤、シロップ剤などの形態で流通に置く
ことができる。実際の服用に際しては、適宜、そのまま
嚥下する、白湯、牛乳、ジュースなどの飲料に溶解、分
散して飲む、他のアミノ酸、水溶性ビタミン類、クエン
酸などの酸味料、砂糖などの甘味料等を添加して、また
適当な風味を加えて飲料にして飲む、ビスケット、ウエ
ハースなどと共に摂食する等の方法によることができ
る。
For example, in the case of oral administration, there is no particular limitation as long as it is a form that can be easily accepted without giving the user uncomfortable feeling, and it is acceptable as the amino acid composition itself having the above composition or pharmaceutically acceptable. Mixed with a carrier, activator, diluent and the like, and placed in the form of powder, granules, tablets, capsules, troches, syrups and the like. When actually taking it, swallow as appropriate, dissolve or disperse in drinks such as hot water, milk, juice, etc., drink other amino acids, water-soluble vitamins, acidulants such as citric acid, sweeteners such as sugar, etc. , And adding a suitable flavor to make a drink, and eating together with biscuits, wafers and the like.

【0022】本発明の褥瘡予防治療用アミノ酸栄養食品
の製造は、これには特別の困難はない。すなわち、医療
食、病者用食品、特定保健用食品などの食品にあるいは
粉末あるいは液体の食品に、これらの製造に際し、先に
説明した褥瘡予防治療用アミノ酸栄養剤におけるものと
同じ種類のアミノ酸を同じ割合で配合することで製造す
ることができる。そして、医療食等と同じ流通形態をと
ることのできることはもちろんである。
There is no particular difficulty in producing the amino acid nutritional food for preventing and treating pressure ulcer of the present invention. In other words, in the manufacture of these foods, such as medical foods, foods for the sick, foods for specified health use, or powdered or liquid foods, the same type of amino acids as those used in the amino acid nutrient for pressure ulcer prevention and treatment described above is used. It can be manufactured by blending in the same ratio. And, needless to say, it can take the same distribution form as medical food and the like.

【0023】本発明の褥瘡予防治療用アミノ酸栄養剤お
よびアミノ酸栄養食品の投与量は、褥瘡の重症度にもよ
るが、先に説明した所定アミノ酸の所定割合の混合物換
算で1日2回、1回当たり0.5〜10g、好ましくは
1.0〜5.0gとすることができる。
The dosage of the amino acid nutrient and amino acid nutritional food for the prevention and treatment of pressure ulcer of the present invention, depending on the severity of the pressure ulcer, is twice a day in terms of a mixture of a predetermined ratio of the predetermined amino acid described above. The amount can be 0.5 to 10 g, preferably 1.0 to 5.0 g per time.

【0024】[0024]

【実施例】以下、実施例により本発明を更に説明する。The present invention will be further described with reference to the following examples.

【0025】実施例1 褥瘡が発生してから1カ月以上経過し、軽快傾向に乏し
い褥瘡症例11例を選択し、5例に対しては、下記第1
表に示すアミノ酸組成の、ある市販の経腸栄養剤を下記
第2表に示す期間1日1800kcal投与し(比較
例)、そして、6例については1日約1200kcal
の食事または前記経腸栄養剤を投与し、加えて第1表に
示す本発明の褥瘡予防治療用アミノ酸栄養剤に所定の組
成のアミノ酸混合物1.4gを1日に2回、朝および夕
食前に下記第3表に示す期間投与した。
Example 1 One or more months have passed since the occurrence of a pressure ulcer, and 11 cases of pressure ulcers with poor remission tendencies were selected.
A commercially available enteral nutrient having the amino acid composition shown in the table was administered at 1800 kcal / day for the period shown in Table 2 below (Comparative Example), and about 1200 kcal / day was given for 6 cases.
And the above enteral nutritional supplement is administered, and in addition, 1.4 g of an amino acid mixture of a predetermined composition is added twice daily to the amino acid nutritional supplement for the prevention and treatment of pressure ulcer of the present invention shown in Table 1 twice a day before breakfast and dinner. Was administered for the period shown in Table 3 below.

【0026】[0026]

【表1】 [Table 1]

【0027】本実施例で使用した本発明のアミノ酸栄養
剤のアミノ酸組成は、いずれも、上表に示す範囲内とし
た。
The amino acid compositions of the amino acid nutrients of the present invention used in the examples were all within the ranges shown in the above table.

【0028】また、前記市販の経腸栄養剤は、窒素源に
L型結晶アミノ酸、熱源としてデキストリンを、さらに
電解質、微量元素ならびにビタミンを加えたもので、脂
肪は必須脂肪酸の補給に必要な量が配合されている。そ
のために消化をほとんど必要とせず、十二指腸、空腸投
与が可能であり、大部分の成分が上部消化管で吸収され
るため残渣が生じず排便量の減少するものである。
The above-mentioned commercially available enteral nutritional supplement is obtained by adding an L-type crystalline amino acid to a nitrogen source, dextrin as a heat source, and an electrolyte, trace elements and vitamins. Is blended. Therefore, little digestion is required, duodenal and jejunal administration is possible, and most components are absorbed in the upper gastrointestinal tract, so that no residue is produced and the amount of defecation is reduced.

【0029】また、これらの投与期間内で褥瘡の処置方
法および、対象者の処遇の変更は行わなかった。投与開
始前に写真撮影、以後2週間毎に写真撮影し、その経過
を観察し、評価した。評価結果(判定)も第2表および
第3表にそれぞれ併記する。
No change was made in the treatment method for pressure ulcers and the treatment of the subjects during these administration periods. Photographs were taken before the start of administration and thereafter every two weeks, and the progress was observed and evaluated. The evaluation results (judgments) are also shown in Tables 2 and 3, respectively.

【0030】[0030]

【表2】 [Table 2]

【0031】[0031]

【表3】 [Table 3]

【0032】アミノ酸栄養剤は、何種類か既に市販され
ている。しかしながら、第2表および第3表から、同じ
アミノ酸を投与しても、本発明に所定のアミノ酸を本発
明に所定の割合で投与する方が、そうでない場合に比較
して、褥瘡治癒に顕著に有効なことが理解することがで
きよう。
Several amino acid nutrients are already commercially available. However, it can be seen from Tables 2 and 3 that even when the same amino acid is administered, it is more remarkable to administer the prescribed amino acid in the present invention at a prescribed ratio to the present invention than in the case where the same amino acid is not administered. Can be understood to be effective.

【0033】また、このことから、本発明の褥瘡予防治
療用アミノ酸栄養剤、および褥瘡予防治療用アミノ酸栄
養食品が病臥者の褥瘡の予防に有効なることも極めて容
易に理解することができよう。
From this, it can be understood very easily that the amino acid nutrient for the prevention and treatment of pressure ulcer and the amino acid nutritional food for prevention and treatment of pressure ulcer of the present invention are effective for prevention of pressure ulcer in a sick person.

【0034】[0034]

【発明の効果】本発明により、褥瘡の優れた全身的療法
剤としての、または優れた褥瘡予防剤としてのアミノ酸
栄養剤が容易に提供されるところとなった。
According to the present invention, an amino acid nutrient as an excellent systemic remedy for pressure ulcers or an excellent agent for pressure ulcer prevention can be easily provided.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】有効成分として、下記アミノ酸を下記割合
(モル比(%))で含有することを特徴とする褥瘡予防
治療用アミノ酸栄養剤:L−アルギニン6.0〜21.
0、L−イソロイシン6.0〜20.0、L−ロイシン
8.0〜25.0、L−バリン6.0〜19.0、L−
リジン1.0〜6.0、メチオニン2.0〜8.0、L
−スレオニン4.0〜13.0、L−ヒスチジン1.0
〜6.0、L−プロリン3.0〜9.0、L−フェニル
アラニン0.2〜1.0、L−トリプトファン0.1〜
1.0およびL−グルタミン8.0〜27.0。
1. An amino acid nutrient for the prevention and treatment of pressure sores: L-arginine 6.0-21.
0, L-isoleucine 6.0-20.0, L-leucine 8.0-25.0, L-valine 6.0-19.0, L-
Lysine 1.0-6.0, Methionine 2.0-8.0, L
-Threonine 4.0-13.0, L-histidine 1.0
~ 6.0, L-proline 3.0 ~ 9.0, L-phenylalanine 0.2 ~ 1.0, L-tryptophan 0.1 ~
1.0 and L-glutamine 8.0-27.0.
【請求項2】有効成分として、請求項1記載のアミノ酸
を同項記載の割合で含有することを特徴とする褥瘡予防
治療用アミノ酸栄養食品。
2. An amino acid nutritional food for preventing and treating pressure ulcers, which comprises the amino acid according to claim 1 as an active ingredient in the ratio described in the same.
JP9295222A 1997-10-28 1997-10-28 Amino acid-based nutrient preparation for preventing/ treating bedsore Pending JPH11130669A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9295222A JPH11130669A (en) 1997-10-28 1997-10-28 Amino acid-based nutrient preparation for preventing/ treating bedsore

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9295222A JPH11130669A (en) 1997-10-28 1997-10-28 Amino acid-based nutrient preparation for preventing/ treating bedsore

Publications (1)

Publication Number Publication Date
JPH11130669A true JPH11130669A (en) 1999-05-18

Family

ID=17817798

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9295222A Pending JPH11130669A (en) 1997-10-28 1997-10-28 Amino acid-based nutrient preparation for preventing/ treating bedsore

Country Status (1)

Country Link
JP (1) JPH11130669A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028531A1 (en) * 2002-09-30 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Preventive or remedy for bedsore
WO2005058306A1 (en) * 2003-12-16 2005-06-30 Riken Glutamine-containing energy imparting amino acid composition or amino acid solution
JP2005272410A (en) * 2004-03-26 2005-10-06 Ajinomoto Co Inc Oral amino acid composition for anti-arteriosclerotic and/or blood rheology improving use
JP2005289928A (en) * 2004-04-01 2005-10-20 Ajinomoto Co Inc Collagen synthesis-promoting amino acid composition
JP2007500208A (en) * 2003-05-22 2007-01-11 エヌ.ブイ.・ヌートリシア Method for treating or preventing chronic wounds and a complete nutritional composition comprising glycine and / or leucine for use therein
WO2008038771A1 (en) * 2006-09-29 2008-04-03 Ajinomoto Co., Inc. Glutamine-containing composition for increasing blood flow
JP2009102235A (en) * 2007-10-22 2009-05-14 Ajinomoto Co Inc Comprehensive nutritional composition
JP2011236240A (en) * 2011-07-08 2011-11-24 Ajinomoto Co Inc Collagen synthesis-promoting amino acid composition
CN115191538A (en) * 2022-07-14 2022-10-18 河北工业职业技术学院 Amino acid beverage and preparation method thereof

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100864384B1 (en) * 2002-09-30 2008-10-20 교와 핫꼬 고교 가부시끼가이샤 Preventive or remedy for bedsore
CN1299679C (en) * 2002-09-30 2007-02-14 协和发酵工业株式会社 Preventive or remedy for bedsore
WO2004028531A1 (en) * 2002-09-30 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Preventive or remedy for bedsore
JP2007500208A (en) * 2003-05-22 2007-01-11 エヌ.ブイ.・ヌートリシア Method for treating or preventing chronic wounds and a complete nutritional composition comprising glycine and / or leucine for use therein
WO2005058306A1 (en) * 2003-12-16 2005-06-30 Riken Glutamine-containing energy imparting amino acid composition or amino acid solution
JP2005272410A (en) * 2004-03-26 2005-10-06 Ajinomoto Co Inc Oral amino acid composition for anti-arteriosclerotic and/or blood rheology improving use
JP2005289928A (en) * 2004-04-01 2005-10-20 Ajinomoto Co Inc Collagen synthesis-promoting amino acid composition
WO2008038771A1 (en) * 2006-09-29 2008-04-03 Ajinomoto Co., Inc. Glutamine-containing composition for increasing blood flow
US7829593B2 (en) 2006-09-29 2010-11-09 Ajinomoto Co., Inc. Glutamine-containing compositions and a method for increasing blood flow using same
EP2077110A4 (en) * 2006-09-29 2012-06-27 Ajinomoto Kk Glutamine-containing composition for increasing blood flow
JP5294149B2 (en) * 2006-09-29 2013-09-18 味の素株式会社 Glutamine-containing composition for increasing blood flow
JP2009102235A (en) * 2007-10-22 2009-05-14 Ajinomoto Co Inc Comprehensive nutritional composition
JP2011236240A (en) * 2011-07-08 2011-11-24 Ajinomoto Co Inc Collagen synthesis-promoting amino acid composition
CN115191538A (en) * 2022-07-14 2022-10-18 河北工业职业技术学院 Amino acid beverage and preparation method thereof

Similar Documents

Publication Publication Date Title
JP3224767B2 (en) Oral zinc composition
US8703725B2 (en) Nutritional compositions
Copeland et al. Nutritional aspects of cancer
JP5315996B2 (en) Total enteral nutrition composition
JP2003522136A (en) Use of glutamate and / or glutamate precursor for the manufacture of a nutritional or pharmaceutical preparation for the treatment or prevention of intestinal wall hyperpermeability or unwanted permeability
EP1797891A1 (en) Total enteral nutritious composition
RU2598630C2 (en) Liquid nutritional composition comprising free amino acids
AU755724B2 (en) Combination of zinc ions and vitamin C and method of making
EP1402788B1 (en) Body temperature-raising agent of amino acids for eating or drinking and for medical use
JPH11130669A (en) Amino acid-based nutrient preparation for preventing/ treating bedsore
JP5100033B2 (en) Gastrointestinal and renal atrophy inhibitor
JP2000063284A (en) Inhibitor against recurrence of inflammatory enteritis
EP2196099B1 (en) Immuno-nutritional composition
JPH02128670A (en) Amino acid-containing food composition
US6793935B2 (en) Mineral supplement
JP2005350371A (en) Nutrient composition for hepatopathic patient
JPWO2004058301A1 (en) Composition for improving swallowing reflex disorder
Sitrin Invented Review: Nutrition Support in Inflammatory Bowel Disease
JPH09110686A (en) Macrophage nitrogen monoxide-producing sthenic agent
JP2001233783A (en) Preoperative nutrient agent
JP4316224B2 (en) Medicinal body temperature raising agent
JPH02128669A (en) Amino acid-containing food composition
JP2004041006A (en) Liquid nutrition composition
JP2004147630A (en) Food
CA2232134A1 (en) Use of threonine for the treatment of phenylketonuria

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070502

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070701

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070701

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070701

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080124